The Centers for Medicare and Medicaid Services is considering a substantive update of the study design requirements for sponsors of treatments that are subject to a Medicare national coverage determination that conditions coverage on further evidence development.
Medicare CED Update Targets Study ‘Efficiency,’ But May Not Ease Data Collection Burden
It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for.
More from Medicare
Since CMMI does not need an executive order to conduct demonstrations, President Trump's executive order does not appear to mean the models developed under the Biden Administration will be suspended, yet.
Speculation that the Trump Administration may "pause" the second negotiation cycle to make changes to the program adds uncertainty to an already challenging scenario.
Medicare Negotiated Drugs Can Face Immediate Generic, Biosimilar Substitution, CMS Proposal Confirms
Stelara, Xarelto, Januvia and Farxiga, which are expected to have biosimilar or generic competition before the end of 2026, could be the first negotiated drugs subject to the policy.
Anti-PBM sentiment continues to rise, but industry observers still question whether the reforms being discussed will be effective.